Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc (NY: NUVB )

1.260 -0.080 (-5.97%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,180
Open 1.340
Bid (Size) 1.260 (1)
Ask (Size) 1.330 (60)
Prev. Close 1.340
Today's Range 1.260 - 1.350
52wk Range 1.180 - 2.545
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nuvation Bio And 3 Other Stocks Under $4 Insiders Are Buying
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire

Performance

YTD
-37.62%
-37.62%
1 Month
-24.10%
-24.10%
3 Month
-28.41%
-28.41%
6 Month
-27.59%
-27.59%
1 Year
-44.49%
-44.49%

More News

Read More
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Analyst Expectations for Nuvation Bio's Future
Via Benzinga
Where Nuvation Bio Stands With Analysts
Via Benzinga
After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program
Via Benzinga
The 7 Worst Stocks to Buy Now
Via InvestorPlace
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
From Nuvation Bio Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
Via Benzinga
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Via Benzinga
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
From Nuvation Bio Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
From Nuvation Bio Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.